Gentris® Corporation, a US company focused on the use of genomic biomarkers in clinical studies, signed a MOU to form a biomarker collaboration with the Shanghai Institutes of Preventative Medicine. The collaboration’s goal is to discover new biomarkers. It will develop translational research and epidemiological projects based on pharmacogenomics and provide clinical sample banking, which are services that Gentris provides to US clients for clinical trials and genomic biomarker programs.
Source: China Biotoday
